Hepatitis C can be transmitted through blood transfusions, organ transplants, percutaneous (especially IV drug use), sexual or perinatal route.
It has an incubation period of 14-180 days.
Goal of treatment is to prevent progression to chronic hepatitis C through antiviral treatment of acute hepatitis C. Also, it aims to prevent occurrence of liver-related complications through antiviral treatment of chronic hepatitis C.
Treatment with the direct-acting antiviral (DAA) combination of glecaprevir and pibrentasvir led to encouraging sustained virological response (SVR) among individuals with hepatitis C virus (HCV) infection, results of two real-world studies presented at the International Liver Congress™ (ILC 2019) showed.
The use of glecaprevir plus pibrentasvir appears to be safe and highly effective in the treatment of chronic hepatitis C virus (HCV) infection genotypes 1–3 in patients with severe renal impairment, including those undergoing haemodialysis, as shown in a recent study from Japan.
Combination treatment with glecaprevir plus pibrentasvirproduces a sustained virological response in more than 90 percent of hepatitis C virus (HCV)-infected patients who previously failed direct-acting antiviral (DAA) treatments, regardless of liver fibrosis stage, a study has shown.
Patients with chronic hepatitis C virus (HCV) infection who are treated with direct-acting antivirals (DAAs) have a reduced risk of all-cause mortality and hepatocellular carcinoma (HCC), according to results of an observational French study.
Achieving sustained virological response in hepatitis C virus (HCV)-infected patients with type 2 diabetes (T2D) substantially cuts the risk of developing acute coronary syndrome, end‐stage renal disease, ischaemic stroke and retinopathy, regardless of cirrhosis, a study has shown.
Antiviral treatment with pegylated interferon and ribavirin leads to a significant reduction in the risk of lymphoma, especially the non-Hodgkin’s type, in patients with chronic hepatitis C virus (HCV) infection, according to a study.
A once-daily oral dose of sofosbuvir and velpatasvir for 12 weeks leads to sustained virological response (SVR) in a majority of patients with chronic hepatitis C virus (HCV) infection, according to an Asian study. However, the efficacy of this regimen may be reduced in patients with HCV genotype 3b with cirrhosis.
Treatment with the combination of the DAAs* glecaprevir and pibrentasvir led to sustained virological response (SVR) in a majority of patients with chronic hepatitis C virus (HCV) infection genotype 5 or 6, according to the phase IIIB ENDURANCE-5,6** trial.
Most liver tumours may be identified at early stages in cirrhotic patients treated with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection, a study reports. Risk factors for increased risk of hepatocellular carcinoma following DAA therapy include male sex, diabetes and noninvasive markers of liver fibrosis.
In patients with genotype 3 hepatitis C virus (HCV) infection and decompensated cirrhosis, the rate of achieving sustained virologic response 12 weeks after treatment (SVR12) is high with treatment regimens consisting of sofosbuvir and velpatasvir with or without ribavirin, according to the results of a phase II trial. However, the rate appears to be lower in the subgroup of patients with baseline resistance-associated substitutions in nonstructural protein 5A.
Electromyographic biofeedback (EMG-BF) appears to be an effective behavioural therapy for improving dyssynergic defecation in chronically constipated community-dwelling elderly women, according to a recent study.
The trend in liver disease-related mortality in individuals with HIV has changed, with a reduction in the incidence of viral hepatitis-related deaths and an increase in non-alcoholic fatty liver disease (NAFLD)-related deaths, according to a study presented at the International Liver Congress™ (ILC 2019).